	US 12,070,472 B2
	Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
Jerry Shay, Dallas, TX (US); Ilgen Mender, Dallas, TX (US); Kimberly Batten, Dallas, TX (US); and Sergei Gryaznov, Chicago, IL (US)
Assigned to The Board of Regents of The University of Texas System, Austin, TX (US)
Filed by The Board of Regents of the University of Texas System, Austin, TX (US)
Filed on Jun. 24, 2019, as Appl. No. 16/450,430.
Application 16/450,430 is a continuation of application No. 15/467,862, filed on Mar. 23, 2017, abandoned.
Claims priority of provisional application 62/312,982, filed on Mar. 24, 2016.
Prior Publication US 2019/0388453 A1, Dec. 26, 2019
Int. Cl. A61K 31/7076 (2006.01); A61K 9/00 (2006.01); A61K 31/7105 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/7076 (2013.01) [A61K 9/0019 (2013.01); A61K 31/7105 (2013.01); A61K 45/06 (2013.01)]

8 Claims

1. A method for treating a resistant non-small cell lung cancer that is telomerase positive, the patient population being characterized by relapse of the cancer within six months of a first line anti-cancer agent, the method comprising administering to the subject

(a) a first amount or dose of 6-thio-2′-deoxyguanosine

and

(b) a second amount or dose of an anti-cancer agent,

wherein the first and second amounts or doses together comprise a therapeutically effective amount of a combination;

wherein the combination is effective to:

reduce size of a tumor, reduce growth rate of a tumor, reduce incidence of metastasis, promote an immune response, reduce progression of the cancer, increase lifespan of the subject, or a combination thereof; and

wherein the anti-cancer agent is an EGFR inhibitor and said non-small cell lung cancer is EGFR resistant prior to treatment with said 6-thio-2′-deoxyguanosine.